# Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT03373019** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 63 (estimated)

## Conditions studied

- Chidamide
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Neoplasm by Histology
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Immune System Diseases
- Lymphoma, Non-Hodgkin
- Cyclophosphamide
- Rituximab
- Gemcitabine
- Cisplatin
- Dexamethasone
- HDAC Inhibitor

## Interventions

- **DRUG:** Chidamide combined with R-GDP

## Key facts

- **NCT ID:** NCT03373019
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-21
- **Primary completion:** 2019-06-30
- **Final completion:** 2021-03-01
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2017-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03373019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03373019, "Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03373019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*